'Future' Of AIDS Vaccine Research In Lab Research, Smaller Trials, Editorial Says

Main Category: HIV / AIDS
Also Included In: Immune System / Vaccines;  Clinical Trials / Drug Trials
Article Date: 02 Apr 2008 - 12:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  


Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


The recent "failure" of a Merck HIV/AIDS vaccine has "led to two conflicting calls for action, neither of which got it right," a Los Angeles Times editorial says. Grant recipients "wanted the vaccine search to go on as before," while "treatment activists wanted the money stripped from research," the editorial says, adding that NIH at a conference last week "appeared to be taking a wiser approach" and said that it "would continue funding vaccine research" with a likely focus on "basic research and smaller, less expensive trials."

After the Merck trial was halted, some groups "lost little time ... in calling for vaccine funding to be rerouted to treatment and prevention," according to the editorial. It adds that U.S. funding for HIV/AIDS vaccine research is less than $700 million annually -- a "relative pittance compared with that for treatment and prevention, which stands at more than $15 billion annually and is expected to at least double in the next year." It is "too easy to forget that people can develop resistance to" antiretroviral drugs and "suffer significant side effects," the editorial says, adding that the "research effort that brought about these treatments was a tremendous achievement, but scientists still have much to learn about the virus."

"It made sense to start the vaccine efforts with big clinical trials that, if successful, would have led quickly to drug licensing" because the "need for a vaccine was urgent," the editorial says, adding, "Now, however, we know that these trials cost too much and take too long." NIH officials are "right to say that the best future for an AIDS vaccine lies in the laboratory and in narrower trials that can point to the most promising paths while they add to our knowledge of the disease," the editorial concludes (Los Angeles Times, 4/1).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Article adapted by Medical News Today from original press release.
Visit our hiv / aids section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "'Future' Of AIDS Vaccine Research In Lab Research, Smaller Trials, Editorial Says." Medical News Today. MediLexicon, Intl., 2 Apr. 2008. Web.
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/102486.php>

APA
Kaiser. (2008, April 2). "'Future' Of AIDS Vaccine Research In Lab Research, Smaller Trials, Editorial Says." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/102486.php.

Please note: If no author information is provided, the source is cited instead.




HIV / AIDS

Most Popular Articles



Follow Our HIV News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our HIV / AIDS Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »